Navigation Links
Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study

ommission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

    For More Information:

    Dr. Chau Cheng

    Associate Director, Investor Relations & Business Analysis

    (973) 605-8200, extension 123
ccheng@immunomedics.com

CONTACT: Dr. Chau Cheng, Associate Director, Investor Relations & BusinessAnalysis, of Immunomedics, Inc., +1-973-605-8200, extension 123, ccheng@immunomedics.com

Web site: http://www.immunomedics.com//

Company News On-Call: http://www.prnewswire.com/comp/113121.html/

Ticker Symbol: (NASDAQ-NMS:IMMU)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
5. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
6. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
7. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
8. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
9. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
10. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
11. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
Post Your Comments:
(Date:9/4/2008)...wswire/ -- Southern Research Institute,today annou...has selected,the organization to participate in th...n Center Network (MLPCN). The MLPCN -- a collabora...Libraries Program which is,designed to benefit hum...an,genome and validate future targets for drug dis...
(Date:9/4/2008)...or Ipilimumab to be Presented, PRINCETON, N.J., S...sdaq: MEDX ) announced today that nine clinical a...TLA-4 antibody, in melanoma are scheduled to be,th... the European Society,for Medical Oncology (ESMO) ...y of the following abstracts will include updated ...
(Date:9/4/2008)...edule with Two Abstracts Accepted for Presenta...2008, BRIDGEWATER, N.J., Sept. 4 /- ...ceutical company focused on the treatment of,cardi...he appointment of,Peter L. Garrambone, Jr. to the ... career includes more than 50 pharmaceutical,trans...
(Date:9/3/2008)...wire-FirstCall/ -- Simcere,Pharmaceutical Group (N...f,branded generic pharmaceuticals and manufacturer...(also known as Endostar) in China,announced the i...At the request of the SFDA, Simcere initiated a Ph...ty and therapeutic efficacy of Endu, a modified,ve...
Breaking Medicine Technology:Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Patients With Asthma and Seasonal Allergies Respond Better to Advair 28R 29 for Their Asthma Than Singulair 28TM 29 2107 1Patients With Asthma and Seasonal Allergies Respond Better to Advair 28R 29 for Their Asthma Than Singulair 28TM 29 2107 2Patients With Asthma and Seasonal Allergies Respond Better to Advair 28R 29 for Their Asthma Than Singulair 28TM 29 2107 3People with obstructive sleep apnea at risk for cardiac stress on airline flights 19674 1People with obstructive sleep apnea at risk for cardiac stress on airline flights 19674 2Body Positive Marks a New Era With Continued Commitment and a New Name 3A The Southwest Center for HIV AIDS 19672 1Body Positive Marks a New Era With Continued Commitment and a New Name 3A The Southwest Center for HIV AIDS 19672 2Body Positive Marks a New Era With Continued Commitment and a New Name 3A The Southwest Center for HIV AIDS 19672 3Sen Edward Kennedy Hospitalized After Seizure 19669 1Sen Edward Kennedy Hospitalized After Seizure 19669 2
...ignificantly,increases patients_ overall survival ...ublished,yesterday in the Journal of Clinical Onco...) was shown to significantly improve,survival in p...chemotherapy alone.1 Follicular lymphoma is the mo...ssing but incurable form of,lymphoma. , The study ...
...ed with,Exforge achieved recommended blood pressur...Hg in,systolic blood pressure observed in patients... monotherapy[1] , Nearly 70% of those with high b...d most require two or more,medications to achieve ... - Exforge®,a single-tablet combination of tw...
Other Medicine Technology:Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma 2Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma 3Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma 4Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 2Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 3Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 4Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 5Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 6Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 7Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 8
(Date:9/4/2008).... Free drug samples provided to physicians by pha...insured patients more in the long run, according t...rsity Baptist Medical Center and colleagues. , T...abits of more than 70 physicians in a university-a... immediately before and after the closing of their...
(Date:9/4/2008)...n a case-control study, the presence of measles vi... and GI disturbances than in children with only GI... onset were unrelated to MMR vaccine timing. Stud...ary of Science on September 4 ( http://dx.plos.or... implementation of measles vaccines in 1963, three...
(Date:9/4/2008)...ence of instructions they say could help doctors e...lthDay News) -- Vaccine safety experts say that al...eive vaccinations with close monitoring and a set ...ptember issue of Pediatrics , a team of experts l...h a step-by-step set of instructions -- an algorit...
(Date:9/4/2008)...ger labeling about fungal infection risk , ...l health authorities have asked the manufacturers ...ster safety warnings on the risk of developing opp...ra, Cimzia, Enbrel and Remicade, belong to a class...ha blockers (TNF-alpha blockers), which suppress t...
Breaking Medicine News(10 mins):Health News:Free drug samples may end up costing uninsured more 2Health News:Free drug samples may end up costing uninsured more 3Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 2Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 3Health News:Even Kids With Known Allergies Can Be Safely Vaccinated 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 3
...olocaust are more likely to suffer from cancer and...d his colleagues at Israel's //Haifa University su...ear-starvation of European Jews during World War I...at the incidence and death rate from cancer in aro...
... of Goan’s can be the main cause for HIV/AIDS spre...ollow the Government policies // and initiatives t...Many labourers who got jobs in Goa, since it has b...ing with them the dreadful virus (HIV) when they a...
...er gave Isabelle Taylor, of St Annes, Lancs, a mob... grand child would end up constantly // sending te...loping a condition known as ‘repetitive strain in...n in Britain to suffer from this condition. Her m...
... researchers plan to ask women to donate their egg... cells matched to patients // which they say would...ng diseases such as diabates or neurodegenerative ...nic stem (ES) cells after creating human embryos c...
Other Medicine News:
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
The Guidant Fineline EZ leads with protective capsule are bipolar endocardial and designed for permanent implantation with pulse generators for cardiac pacing.
Medicine Products: